Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 10/20 | 0.48 |
| ▸ | RXRG | P48443 | 5/20 | 0.48 |
| ▸ | RXRB | P28702 | 4/20 | 0.48 |
| ▸ | CYP26A1 | O43174 | 9/20 | 0.42 |
| ▸ | CYP26B1 | Q9NR63 | 8/20 | 0.39 |
| ▸ | RARA | P10276 | 2/20 | 0.36 |
| ▸ | RARB | P10826 | 4/20 | 0.36 |
| ▸ | RARG | P13631 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HNF4A | P41235 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8450973 | 0.78 | MPO (0.33) | RXRARXRGRXRB | |
| SCHEMBL6913577 | 0.78 | RXRA (0.60) | RXRARXRGRXRBRARARARB | |
| SCHEMBL7922871 | 0.77 | RXRA (0.39) | RXRARXRGRXRBCYP26A1CYP26B1 | |
| SCHEMBL6037047 | 0.76 | RXRA (0.52) | RXRARXRGRXRBRARARARB | |
| SCHEMBL6037045 | 0.76 | RXRA (0.52) | RXRARXRGRXRBRARARARB | |
| SCHEMBL10078298 | 0.75 | MPO (0.52) | — | |
| SCHEMBL6037052 | 0.72 | RXRA (0.34) | RXRARXRGRXRBCYP26A1CYP26B1 | |
| SCHEMBL6037056 | 0.72 | RXRA (0.34) | RXRARXRGRXRBCYP26A1CYP26B1 | |
| SCHEMBL8973409 | 0.72 | TDP1 (0.41) | — | |
| SCHEMBL3452288 | 0.71 | MPO (0.67) | CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0933351-A1 | Tricyclic retinoids, methods for their production and use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0933350-A1 | Tricyclic retinoids, methods for their production and use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-08-04 | — | — | EP | disclosed |
| US-5770382-A | RETINOIC ACID AND RETINOID X RECEPTOR AGONISTS; TREATINGSKIN, EYE, BRAIN, AND CARDIOVASCULAR DISORDERS; CANCER | LIGAND PHARMACEUTICALS, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| US-5770378-A | A VITAMINE A METABOLITE, POTENT DRUGS TREATING SKIN DISEASES, CANCER, EYE DISEASES, CARDIOVASCULAR DISORDERS | LIGAND PHARMACEUTICALS, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| US-5770383-A | ACTIVATE RETINOID RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| EP-0800504-A1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996020914-A1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-07-11 | — | — | WO | disclosed |